Coronary Artery Calcium Score for Personalization of Antihypertensive Therapy
Vibhu ParchaGargya MallaRajat KalraPeng LiAmbarish PandeyKhurram NasirGarima AroraPankaj AroraFrom the Division of Cardiovascular Disease,University of Alabama at Birmingham (V.P.,P.A.)Department of Epidemiology,University of Alabama at Birmingham (G.M.)School of Nursing,University of Alabama at Birmingham (P.L.)Cardiovascular Division,University of Minnesota,Minneapolis (R.K.)Division of Cardiology,Department of Internal Medicine,UT Southwestern Medical Center,Dallas,TX (A.P.)Division of Cardiovascular Prevention and Wellness,Houston Methodist DeBakey Heart and Vascular Center,TX (K.N.)Center for Outcomes Research,Houston Methodist Research Institute,Houston,TX (K.N.)Section of Cardiology,Birmingham Veterans Affairs Medical Center,AL (P.A.).
DOI: https://doi.org/10.1161/hypertensionaha.120.16689
IF: 9.8968
2021-03-03
Hypertension
Abstract:The 2017 American College of Cardiology/American Heart Association high blood pressure (BP) guidelines recommend risk assessment of atherosclerotic cardiovascular disease to inform hypertension treatment in adults with elevated BP or low-risk stage I hypertension. The use of coronary artery calcium (CAC) score to guide hypertension therapy has not been adequately evaluated. Participants free of cardiovascular disease were pooled from Multi-Ethnic Study of Atherosclerosis, Coronary Artery Risk Development in Young Adults, and Jackson Heart Study. The risk for incident cardiovascular events (heart failure, stroke, coronary heart disease), by CAC status (CAC-0 or CAC>0) and BP treatment group was assessed using multivariable-adjusted Cox regression. The 10-year number needed to treat to prevent a single cardiovascular event was also estimated. This study included 6461 participants (median age 53 years; 53.3% women; 32.3% Black participants). Over a median follow-up of 8.5 years, 347 incident cardiovascular events occurred. Compared with those with normal BP, the risk of incident cardiovascular event was higher among those with elevated BP/low-risk stage I hypertension and CAC>0 (hazard ratio, 2.4 [95% CI, 1.7–3.4]) and high-risk stage I/stage II hypertension (BP, 140–160/80–100 mm Hg) with CAC>0 (hazard ratio, 2.9 [95% CI, 2.1–4.0]). A similar pattern was evident across racial subgroups and for individual study outcomes. Among those with CAC-0, the 10-year number needed to treat was 160 for elevated BP/low-risk stage I hypertension and 44 for high-risk stage I or stage II hypertension (BP, 140–160/80–100 mm Hg). Among those with CAC>0, the 10-year number needed to treat was 36 and 22, respectively. Utilization of the CAC score may guide the initiation of hypertension therapy and preventive approaches to personalize cardiovascular risk reduction among individuals where the current guidelines do not recommend treatment.
peripheral vascular disease